Klinik für Innere Medizin V, Pneumologie, Allergologie und Respiratorische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
J Cyst Fibros. 2011 Jun;10 Suppl 2:S146-51. doi: 10.1016/S1569-1993(11)60019-2.
Chronic infection of the respiratory tract is a hallmark of cystic fibrosis (CF). Antibiotic treatment has been used as one of the mainstays of therapy and together with other treatment modalities has resulted in increased survival of CF patients. Increasing resistance of CF-specific pathogens to various classes of antibiotics explains the need for novel antibiotic strategies. This review focuses on the future development of new antibiotic therapies, including: (1) New targets, (2) novel antibiotic regimens in CF, (3) new antibiotics, and (4) other investigational therapies. In addition, we briefly summarize developments in the area of microbial diagnostics and discuss interactions between the complex pulmonary microflora.
呼吸道慢性感染是囊性纤维化(CF)的一个标志。抗生素治疗一直是治疗的主要方法之一,与其他治疗方式一起,使 CF 患者的生存率提高。CF 特定病原体对各种类别的抗生素的耐药性增加解释了需要新的抗生素策略。这篇综述重点介绍了新抗生素治疗方法的未来发展,包括:(1)新靶点,(2)CF 中的新型抗生素方案,(3)新型抗生素,和(4)其他研究性治疗。此外,我们简要总结了微生物诊断领域的发展,并讨论了复杂的肺部微生物群落之间的相互作用。